Use of an miRNA to reduce proliferation of a cancer cell
View Patent ↗A method is provided for decreasing at least one of the proliferation and the migration of a cancer cell comprising contacting a cancer cell with an effective amount of a pharmaceutically acceptable composition comprising a microRNA (miRNA) having a nucleotide sequence having at least 80% sequence similarity to the nucleotide sequence of miR-3189-3p derived from the miR-3189 mitron of the Growth Differentiation Factor 15 (GDF15) gene. The methods and compositions are advantageous for inhibiting proliferation and migration of, but not limited to, glioblastoma cells, melanoma cells, and breast cancer cells.
1. A method for decreasing at least one of the proliferation and the migration of a glial tumor cell, comprising contacting the cancer cell with a pharmaceutically acceptable composition comprising a microRNA (miRNA) having the nucleotide sequence SEQ ID NO: 2, thereby decreasing at least one of the proliferation and migration of the cancer cell as compared to a control.
2. The method of claim 1 , wherein the glial tumor cell is an astrocytoma tumor cell, an ependymal tumor cell, a glioblastoma multiforme tumor cell, or a primitive neuroectodermal tumor cell.
3. The method of claim 2 , wherein the glioblastoma multiforme is located in the brain or the spinal cord of the subject.
4. The method of claim 1 , wherein the miRNA reduces the expression of at least one of p63RoGEF and SF3B2 splicing factor in the cancer cell, or modulates the effect of MYC in the cancer cell.
5. The method of claim 1 , wherein the cancer cell is an isolated cancer cell, a cultured cell, a cell in a tissue of an animal or human patient, or progeny thereof.
6. A method for treating a cancer, wherein the cancer is a glial tumor, the method comprising administering to an animal or human subject in need thereof an effective amount of a pharmaceutically acceptable composition consisting essentially of a microRNA (miRNA) having the nucleotide sequence SEQ ID NO: 2, thereby decreasing at least one of the proliferation and migration of the cancer cell as compared to a control.
7. The method of claim 6 , wherein the glial tumor cell is an astrocytoma tumor cell, an ependymal tumor cell, a glioblastoma multiforme tumor cell, or a primitive neuroectodermal tumor cell.
8. The method of claim 6 , wherein the glioblastoma multiforme is located in the brain or the spinal cord of the subject.
9. The method of claim 6 , wherein the miRNA reduces the expression of at least one of p63RoGEF and SF3B2 splicing factor in the cancer cell, or modulates the effect of MYC in the cancer cell.
10. The method of claim 6 , wherein the pharmaceutically acceptable composition is administered to the animal or human subject intravenously, subcutaneously, or intratumorally.
11. The method of claim 6 , wherein the pharmaceutically acceptable composition is formulated to deliver the miRNA across the blood-brain barrier or to deliver the miRNA as a nucleic acid expression product to the cells of the cancer.